A Decade in the Anti-Obesity Arena
Currax Pharmaceuticals CEO, George Hampton discusses what patient success has looked like for their oral anti-obesity medication, how expanded access can help with the world's obesity epidemic, when prices should come down, and much more.
In this episode of the Pharmaceutical Executive Podcast, Currax Pharmaceuticals CEO, George Hampton discusses:
- Contrave
- What patient success has looked like
- How different kinds of therapies perform and fit in the current business landscape
- Ethical and regulatory problems for weight loss companies like WW, Noom, and Ro present
- How can access to these weight loss drugs help the obesity epidemic
- and much more!
Recent Videos
Related Content
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Podcast
Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
